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intermittent hemodialysis either at home or in-center
[5].
We think that the difference in experiences between
the two eras relates to several factors. First, it has been
demonstrated that many biochemical and clinical param-
eters including quality-of-life are improved by quotidian
hemodialysis [6]. Second, as the number of programs of-
fering quotidian hemodialysis has grown, the exposure of
nephrologists and trainees to the method has increased,
resulting in a larger pool of nephrologists capable of
supervising these modalities. Third, the use of the button-
hole technique has helped resolve access difficulties in-
herent in daily hemodialysis. Fourth, industry interest has
also increased, resulting in equipment that has simplified
home hemodialysis techniques. Of course, the most im-
portant driver of growth has been patient interest, which
has risen as patients have heard of others doing well on
home-based hemodialysis.
The full potential for growth in quotidian hemodialy-
sis will not be realized until reimbursement issues have
been resolved. Although we have demonstrated that a
potential for cost savings at the global health care level,
local funding for hemodialysis consumables and capi-
tal will need to be increased [7]. We believe that when
the financial obstacles are removed and more patient-
friendly hemodialysis machines become available, quo-
tidian nocturnal and short-daily hemodialysis will be-
come the modalities of choice for an even larger number
of patients.
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Components of the IGF
system and not insulin itself
are strongly associated with
apoB100 kinetics in ESRD
To the Editor: In our accompanying paper in this is-
sue of Kidney International, insulin sensitivity tended to
be lower both in end-stage renal disease (ESRD) and in
peritoneal dialysis (PD) compared to controls. Addition-
ally, apoB100 kinetics was not associated with indexes
of insulin sensitivity. Insulin growth factors (IGFs) and
the binding proteins (IGFBPs) are key regulators of fetal
growth and development [1]. However, recently the IGF
system has been associated with metabolic pathways that
exhibit expression of a prodiabetic/proatherogenic phe-
notype [2].
Therefore, we aim to observe additional key pathways
that may be involved in the origin of dyslipidemia in pa-
tients with ESRD.
Plasma levels of IGF-1 (239 ± 12, 255 ± 44, 115 ± 12 ng/
mL), IGF-2 (658 ± 33, 765 ± 77, 470 ± 35 ng/mL),
IGFBP1 (51 ± 9, 44 ± 6, 24 ± 5 lg/L), and IGFBP3 (4.0 ±
0.2, 5.5 ± 0.5, 2.1 ± 0.2 mg/L) are all significantly higher
(P < 0.05) both in ESRD and PD compared with controls.
Significant associations were found between parameters
of the IGF system and apoB100 kinetics (Table 1). Strong
negative associations for absolute synthesis rate (ASR)
VLDL-2 apoB100, fractional catabolic rate (FCR)
VLDL-2 apoB100, transfer to IDL apoB100 and IGF-1,
IGF-2, and IGFBP3 were observed. In addition, ASR
VLDL-1 apoB100 correlated positively with IGF-1 and
IGFBP3.
These results suggest a key role for circulating IGFs
and IGFBPs involved in apoB100 kinetics. IGFBP3 ap-
peared to be involved in all found associations. Indeed,
IGFBP3 is bound in complex with either IGF-1 or IGF-2.
IGFBP3 has intrinsic properties on nuclear receptors, and
the uptake of IGFBP3 is facilitated by cholesterol in cave-
olins. Because insulin stimulates IGFBP3 synthesis [3], it
may therefore be indirectly involved in these metabolic
pathways.
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Table 1. Associations between parameters of the IGF-system and apoB100 kinetics in patients and control subjects
ASR VLDL-1 FCR VLDL-1 DC VLDL-1 Transfer to ASR VLDL-2 FCR VLDL-2 DC VLDL-2 Transfer to IDL
apoB100 apoB100 apoB100 VLDL-2 apoB100 apoB100 apoB100 apoB100 apoB100
mg/kg/day pools/day pools/day pools/day mg/kg/day pools/day pools/day pools/day
IGF-1 ng/mL r2 = 0.32 XXX XXX XXX r2 = 0.29 r2 = 0.24 XXX r2 = 0.27
(P = 0.02) (P = 0.02) (P = 0.04) (P = 0.03)
IGF-2 ng/mL XXX XXX XXX XXX r2 = 0.46 r2 = 0.57 XXX r2 = 0.53
(P = 0.003) (P < 0.001) (P < 0.001)
IGFBP1 lg/L XXX XXX XXX XXX XXX XXX XXX XXX
IGFBP3 mg/L r2 = 0.27 XXX XXX XXX r2 = 0.47 r2 = 0.62 XXX r2 = 0.57
(P = 0.03) (P = 0.002) (P < 0.001) (P < 0.001)
Abbreviations are: ASR, absolute synthesis rate; FCR, fractional catabolic rate; DC, direct catabolism; XXX, no significant correlation found.
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